Table 1.
Clinical trials of immunotherapy for ovarian cancer.
| Interventions | Number | Phase | Status | Efficacy | |
|---|---|---|---|---|---|
| Immune Checkpoint Blockade | Ipilimumab | NCT01611558 | Phase 2 | Completed | BOR: 15% |
| Nivolumab | UMIN000005714 | Phase 2 | Completed | BOR: 15% ORR: 10% (1 mg/kg), 20% (3 mg/kg) PFS: 3.5 months OS: 20.0 months |
|
| Pembrolizumab | NCT02674061 | Phase 2 | Completed | ORR: 7.4% (received 1-3 prior lines), 9.9% (received 4-6 prior lines) DCR: 37.2% (received 1-3 prior lines), 37.4% (received 4-6 prior lines) |
|
| Pembrolizumab + Niraparib (PARP inhibitor) | NCT02657889 | Phase 1/2 | Completed | ORR: 18% DCR: 65% |
|
| Durvalumab + Trabectedin | NCT03085225 | Phase 1 | Active, not recruiting | tumor shrinkage rate: 43% ORR: 21.4% 6-month PFR: 42.9% |
|
| Pembrolizumab + Pegylated liposomal doxorubicin | NCT02865811 | Phase 2 | Active, not recruiting | CBR: 52.2% ORR: 26.1% |
|
| Nivolumab + Bevacizumab (antiangiogenic agent) | NCT02873962 | Phase 2 | Recruiting | ORR: 40.0% (platinum-sensitive participants), 16.7% (platinum-resistant participants) PFS: 8.1 months |
|
| Cancer Vaccines | MUC1-targeted DC vaccine | NCT01068509 | Phase 2 | Completed | PFS:13 months (first clinical remission), >42 months (second clinical remission) |
| Multivalent conjugate vaccine (MUC1-TN, GLO-H, GM2, TF) + OPT-821 (saponin-based immunoadjuvant) | NCT00857545 | Phase 2 | Completed | HR of PFS: 0.98 OS: 47 months |
|
| Multiepitope FRα vaccine + durvalumab | NCT02764333 | Phase 2 | Completed | SD: 33.3% PR: 3.7% |
|
| Oxidized whole-tumor lysate DC vaccine | NCT01132014 | Early phase 1 | Completed | SD: 52.0% PR: 8.0% 2-year OS: 100% (responders), 25% (nonresponders) |
|
| Adoptive cell therapy | TIL + lymphodepleting chemotherapy (cyclophosphamide and fludarabine) + IL-2 | NCT02482090 | Phase 1 | Completed | 3-month SD: 66.7% 5-month SD: 33.3% decrease in target lesions: 33.3% |
| TIL + cyclophosphamide | / | CR: 14.3% PR: 57.1% |
|||
| TIL + lymphodepleting chemotherapy (cyclophosphamide and fludarabine) + IL-2 + Ipilimumab + Nivolumab | NCT03287674 | Phase 1/2 | Completed | 12-month SD: 83.3% PR: 16.7% |
|
| CAR-T targeting mesothelin | NCT02159716 | Phase 1 | Completed | BOR: 73.3% | |
| Cytokines | Recombinant IL-2 | / | Phase 2 | Completed | ORR: 25.0% |
| α-Recombinant interferon | / | Phase 3 | Completed | CR: 36% PR: 9% PD: 55% |
|
| IFN-γ + cisplatin + cyclophosphamide | / | Phase 3 | Completed | CR: 68% 3-year PFR: 51% 3-year OS: 74% |
|
| IL-2 + OK-432 + platinum- and Taxol-based chemotherapy | Case report | / | Completed | recurrence rate: 53.8% (immunochemotherapy), 88% (traditional chemotherapy) | |
| IL-18 + pegylated liposomal doxorubicin | NCT00659178 | Phase 1 | Completed | SD: 38% PR: 6% |
|
| IL-2 + 13-cis-retinoic acid | / | Phase 2 | Completed | 5-year PFS: 29% OS: 38% |
BOR, Best Overall Response Rate; ORR, Objective Response Rate; PFS, Progression-Free Survival; OS, Overall Survival; DCR, Disease Control Rate; PFR, Progression-free Rate; CBR, Clinical Benefit Rate; HR, Hazard Ratio; SD, Stable Disease; PR, Partial Response; CR, Complete Response.